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Summary
We performed a trial using the combination of epirubicin 50
mg/m2/day 1, carboplatinum AUC 5/day 1 and continuous
5-fluorouracil (5-FU) 200 mg/m2/day (every 4 weeks for
6 months) to confirm the efficacy and low toxicity profile of
this regimen in breast cancer. In 51 patients with metastatic
(n = 33) or locally advanced (« = 18) breast cancer the overall
response rate was 86% (95% confidence interval (95% CI):
73%-94%): 94% in locally advanced and 81% metastatic dis-
ease. Grade 3-4 toxicity was low: 4% of patients presented
with febrile neutropenia, 16% with severe palmar-plantar syn-
drome, 10% with Port-a-cath thrombosis.
This study confirms the high efficacy of infusional 5-FU-
based regimens and justifies further research into novel prom-
ising oral 5-FU derivatives.
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Introduction
Conventional polychemotherapy regimens induce re-
sponse rates of 50%-60% in stage III and IV breast
cancer [1]. Such regimens often include 5-fluorouracil
(5-FU), which is commonly administered as a bolus.
Continuous infusion 5-FU helps to overcome its short
half-life, and can give response rates of 30% even in
heavily pre-treated patients with metastatic breast cancer
[2, 3]. Administered in continuous infusion, 5-FU has
been successfully combined with cisplatinum, possibly
because of a synergistic interaction [4-6]. Furthermore
the Royal Marsden Hospital (London) has demon-
strated considerable activity for the combination of
epirubicin, cisplatinum and continuous infusion 5-FU
in the treatment of breast cancer [5-8]. More recently
carboplatinum has been substituted for the cisplatinum,
allowing for outpatient treatment, reducing the risk
of serious emesis, nephrotoxicity and neurotoxicity [7].
However, the efficacy demonstrated in phase II studies
conducted in tertiary referral centers does not always
survive translation to less specialized units; therefore, a
confirmatory trial of the combination of epirubicin (E),
carboplatinum, and infusional 5-FU was performed in
two general hospitals in Switzerland.
Patients and methods
Patients
Patients referred to the oncology division of two general hospitals
in Switzerland (Hopital Cantonal Universitaire de Geneve, Hopital
Regional de Sion) with histologically or cytologically documented
locally advanced/inflammatory breast cancer (LABC) or metastatic
breast cancer (MBC) were considered for this study. The criteria for
LABC were those defined by Haagensen and Stout [9]. Inflammatory
breast cancer was defined as aT4 lesion with diffuse brawny induration
of the skin with an erysipeloide edge [10]. Patients with LABC were
considered eligible if they had received no previous therapy, whereas
patients with metastatic disease could have received prior endocrine
therapy but no chemotherapy for metastatic disease.
Additional inclusion criteria were age < 70, World Health Organ-
ization (WHO) [11] performance status 0-2, adequate haematological,
renal and liver function (i.e., WBC counts > 3.0 x 109/l, platelet count
> 100 x 109/l, creatinine clearance >60 ml/min, bilirubin <1.25 x
upper normal limit, hepatic enzymes < 2 x normal upper limit), at
least one measurable lesion (at least 10 x 10 mm in diameter) and
ability to manage an indwelling intravenous catheter. Patients with
cerebral metastasis were eligible for inclusion provided there was no
major neurologic deficit. The protocol was approved by local Ethics
Committee.
Treatment
A Port-a-cath was inserted into the subclavian vein to allow the
continuous delivery of infusional 5-FU 200mg/m2/day for six months,
using a seven day infusor device (Baxter 7 days infusor: ref: 2C1082K.J,
Irvine. USA), which was replaced weekly. Epirubicin (50 mg/m2) and
carboplatinum (given at AUC 5, over one hour) were given every four
weeks for six courses. The carboplatinum dose administered was
calculated as 5 x (GFR + 25) (as per Calvert [12]) using a GFR
(glomerular filtration rate) estimated according to the Cockroft &
Gault formula:
GFR = 1.1 x (140 — age) x weight
serumcreatinine (umol/1)
Routine antiemetics (dexamethasone 10 mg and HT3 antagonists) were
administered 30 minutes before the epirubicin and carboplatinum.
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Table I. Patient characteristics.
Metastatic Locally
advanced
Number of patients
Age (years)
Median
Range
Performance status
0
1
2
Menstrual status
Pre
Post
Site of disease
Local
Breast
Regional nodes
Chest wall
Distant
Soft tissue/distant nodes
Bone
Lung
Liver
Other
Hormonal receptors
ER+
PR+
Previous adjuvant chemotherapy
Previous endocrine treatment
Interval between diagnosis and
metastasis (months)
Range
33
55
29-69
19
11
3
9
24
13
8
8
2
17
13
6
16
2
18/28
14/26
12
10
30
3.5-109
18
53
31-69
16
2
0
10
8
18
16
14
1
9/16
10/16
0
Response was assessed according to WHO criteria [11] after every
two cycles, and on completion of treatment (or discontinuation). Partial
and complete responses were confirmed after one month. Patients were
then monitored at two month intervals.
Dose modifications
In case of leucopenia <3.0 x 1O9/1, thrombocytopenia < 100 x 109/l,
on day 1 of each subsequent cycle 5-FU was continued but carboplati-
num and epirubicin were delayed for one week. If after one week, the
blood count had not recovered, treatment was delayed a further week
and a dose reduction was undertaken: epirubicin and 5-FU were
reduced by 25% and carboplatinum to AUC 4. If low blood count
lasted for more than 2 weeks, epirubicin and 5-FU were reduced by
50% and carboplatinum to AUC 3.
For mild to moderate palmo-plantar syndrome (dryness: grade 1,
erythema with pain: grade 2), the 5-FU was continued with the
addition of pyridoxine (50 mg orally 3 td). For severe palmo-plantar
syndrome (erythema with blistering and desquamation: grade 3)
pyridoxine was started and 5-FU withheld until healing occurred.
Then 5-FU was restarted at 25% dose reduction and pyridoxine
continued throughout the treatment. For WHO grade 3 or 4 mucositis
or persistent diarrhoea, 5-FU was discontinued for one week and
restarted at a 25% dose reduction. Epirubicin was also subsequently
given at a 25% dose reduction.
Statistical considerations
This was an open-ended phase II study, with a planned minimum
recruitment of 50 patients so that the 95% confidence interval would
be ± 25% for an anticipated response rate of 85%. Time to progression
and survival were calculated using the Kaplan-Meier method, with
time to progression defined as the time elapsed between the start of
treatment and the date of progression or the date of last evaluation.
Antiseptic mouthwash and nystatin (4 times per day) were used in
order to decrease the risk of oral mucositis. Patients were started on
warfarin (1 mg/day p.o.) since this compound has been shown to
decrease the risk of thrombosis associated with an indwelling line [13].
For patients with locally advanced breast cancer (LABC), loco-
regional treatment was performed on completion of chemotherapy.
Whenever possible, this consisted of surgery (tumorectomy or radical
mastectomy + axillary dissection) followed by radiotherapy to the
breast (or chest wall after mastectomy) and regional lymph node areas.
On completion of chemotherapy, all patients with potentially hormone-
sensitive disease (estrogen receptor or progesterone receptor positive
tumors > 10% by immunohistochemistry) were given hormonal ther-
apy. For patients with LABC, hormonotherapy consisted of tamoxifen
(20 mg/day) for five years whereas for those patients with metastatic
disease, tamoxifen or aromatase inhibitors were given, depending on
prior therapy, until progression.
Assessment of response and toxicity
Initial staging included clinical examination, blood tests according
to inclusion criteria, liver ultrasound or abdominal computed tomo-
graphic scan, chest X-rays, bone scan scintigraphy and bone X-rays on
hot spots.
Toxicity was assessed according to WHO criteria [11]. Patients had
a physical examination, a full blood count, blood chemistry (renal and
liver tests) before each cycle. A full blood count was repeated on day 8
and 14.
Port-a-cath thrombosis grade 3 was defined as requiring hospital-
ization and grade 4 as life threatening thrombosis. Port-a-cath infec-
tion grade 3 was defined as requiring hospitalization for i.v. antibiotics
and grade 4 requiring removal of line.
Results
Patient characteristics
Between January 1996 and July 1998, 51 eligible patients
were registered in this study. Forty-two were treated in
Geneva and nine in Sion. Patient characteristics are
listed in Table 1. The median age was 53 years (range
29-69). Nineteen patients were pre-menopausal and
thirty-two were peri- or post-menopausal. Eighteen
(35%) patients had LABC and thirty-three (65%) had
metastatic disease: seventeen at diagnosis and sixteen
had relapsed after a median time of thirty months (range
3.5-109) following primary treatment. Twelve patients
with metastatic disease had received prior adjuvant
chemotherapy: cyclophosphamide, methotrexate, 5-FU
(CMF) in two; chlorambucil, methotrexate. 5-FU
(LMF) in one; adriamycin, cyclophosphamide (AC) in
three; cyclophosphamide, adriamycin, 5-FU (CAF) in
one; cyclophosphamide, epirubicin, 5 FU (CEF) in two;
AC + CMF in three. Ten patients had been previously
given endocrine therapy for metastatic disease before
entering the study.
All patients were assessable for response and toxicity,
except one, who received only one week of treatment.
She could not tolerate the seven-day infusor for psycho-
logical reasons.
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Table 2. Response. 1.0
Number of patients
CR
PR
OR
SD
PD
Metastatic.
n (%)
32
5(16)
21 (66)
26(81)
6(19)
0(-)
Locally advanced.
n (%)
18
5(28)
12(67)
17(94)
1(6)
0(-)
Abbreviations: CR - complete response: PR - partial response; OR
overall response: SD - stable disease; PD - progressive disease.
Table 3. Toxicity, worst score for any course of treatment (expressed as
number of patients having had that score).
WHO grade 1-2.
n (%)
WHO grade 3-4,
n (%)
Anaemia
Neutropenia
Thrombocytopenia
Infection
Emesis
Stomatitis
Plantar-palmar syndrome
Alopecia
Port-a-cath thrombosis
Port-a-cath infection
Diarrhoea
37 (74)
9(18)
15(30)
8(16)
27 (54)
19(38)
12(24)
13(26)
2(4)
OH
8(16)
8(16)
38 (76)
21 (42)
2(4)
9(18)
3(6)
8(16)
32 (64)
5(10)
0(-)
1(2)
Response
The overall response rate was 86% (43 of 50 patients)
(95% confidence interval (95% CI): 73%-94%). LABC
patients achieved a 94% response rate: 5 (28%) had a
clinical complete response (CR), while 12 (67%) had a
partial response (PR). One had stable disease (SD).
Metastatic patients had a 81% response rate: 5 (16%)
had a CR, 21 (66%) had a PR. Six had a SD (Table 2).
Seven of the twelve patients who previously received
adjuvant chemotherapy achieved a 58% response rate
(95% CI: 28%-85%), while 19 of the 21 chemotherapy-
naive patients achieved 90% response rate (95% CI:
70%-99%).
Median follow-up was 22 months. One- and two-year
survival rates were 94% (95% CI: 81%-98%) and 69%
(95% CI: 47%-83%) respectively (Figure 1). One- and
two-year time to progression (TTP) rates were 65%
(95% CI: 49%-77%) and 44% (95% CI: 24%-61%),
respectively (Figure 2). In LABC patients, one- and
two-year survival rates were 100%, TTP rates were 94%
and 70%, respectively. In metastatic patients one- and
two year survival rates were lower at 90% and 50%,
respectively; TTP rates were 47% and 28%, respectively
(Figures 1 and 2). In LABC patients median TTP was
not reached; in metastatic patients median TTP was 11
months.
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Figure I. Overall survival of 51 breast cancer patients treated with
EcarboF regimen; • - overall survival of 33 metastatic breast cancer
patients; O - overall survival of 18 locally advanced breast cancer
patients.
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Figure 2. Time to first event for 51 breast cancer patients treated with
EcarboF regimen; • - time to first event for 33 metastatic breast
cancer patients; O - time to first event for 18 locally advanced breast
cancer patients.
Toxicity
Details of toxicity are listed in Table 3. Although
neutropenia grade 3-4 was observed in 76% of the
patients, febrile neutropenia occurred in only 4%.
Thrombocytopenia grade 3-4 occurred in 42% of the
patients, but no platelet transfusions were required and
no haemorrhagic episodes were observed. In MBC
compared to LABC, anaemia and neutropenia rates
were comparable. Nausea and vomiting grade 3-4 were
seen in 18% of the patients, severe stomatitis in only
three patients and diarrhoea in one. Severe palmo-plan-
tar syndrome was observed in 16%. No port-a-cath
infection occurred and only five (10%) grade 3 thrombo-
ses were observed. Thirty-two patients had alopecia that
required wearing a wig. One patient experienced an
anaphylactic reaction during first injection of bolus
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epirubicin, where in subsequent cycles mitoxantrone
was substitued for the epirubicin.
Dose reductions and treatment delays
Treatment was delayed in 14 patients (28%). 5-FU
dosage was reduced in 23 patients (46%) because of
palmar-plantar syndrome (7 patients), stomatitis (4
patients) and neutropenia or thrombocytopenia (12 pa-
tients). The 32 patients who completed at least 6 chemo-
therapy cycles had a mean and median total dose of 50 g
of 5-FU administered (range 25-71 g; first and third
quartile: 42-55 g).
Eighteen patients stopped their treatment early. The
treatment was interrupted in five for toxicity (Port-a-
cath thrombosis in 2; early and severe palmar-plantar
toxicity in 1; thrombocytopenia: grade 3; severe asthenia
associated with a psychological depression in one).
Another five patients stopped treatment early because
of progressive disease following an initial response. In
seven additional patients treatment was stopped early by
the physician (one patient was in CR, she received a
total of four cycles; two patients were in partial remis-
sion (PR) they received five cycles; in four patients there
was no change (NC), they received three, four and two
of them five cycles). One metastatic patient who had PR
returned to her home country after four cycles of treat-
ment and hence was lost to follow-up.
Discussion
This study conducted in two general hospitals, confirms
the high response rate with the EcarboF regimen previ-
ously reported from a tertiary care hospital [7]. For
patients with metastatic disease, the response rate was
similar in the two studies, with 81% overall response
including 16% CR in our study and 17% CR in the Royal
Marsden Hospital (RMH) trial. In LABC patients the
response rate was 94% and 81%, respectively. As in the
British trial we report few clinically relevant toxic epi-
sodes. The rate of febrile neutropenia was 4% in this
study and 11% in the RMH trial. We report no severe
central line infection compared to a 6%-17% infection
rate in the RMH study. The use of a Port-a-cath instead
of a Hickman line may account for this difference.
The rate of severe central line thrombosis requiring
hospitalization was 10%, but without any life threat-
ening episodes. This is similar to the rate reported across
a number of studies conducted at the RMH with infu-
sional 5-FU delivered through a Hickman line [5-8, 14].
Interestingly, the rate of Port-a-cath thrombosis in the
literature seems similar whether chemotherapy is ad-
ministered as a bolus or as a continuous infusion: 8.1%
among 132 patients receiving various bolus chemother-
apy regimens and 4.7% among 149 patients who received
infusional chemotherapy [15,16].
Chemotherapy is given with palliative intent in meta-
static breast cancer, and therefore optimal management
requires a balance between activity and tolerability. In
this regard, infusional 5-FU-based regimens have a
favorable therapeutic index: in terms of efficacy, the
phase II results obtained in a number of centers demon-
strate that this approach is associated with response
rates of 70% to 80% [5, 7, 8] suggesting activity similar
to regimens containing anthracycline & taxane combi-
nations [17]. However, with paclitaxel-doxorubicin
combination the risk of cardiotoxicity is a concern [18],
whereas with docetaxel-anthracycline combinations
without G-CSF the rate of febrile neutropenia episodes is
high at around 10% [19] per cycle or 38% of patients [20].
Considering the high response rate of ECarboF regi-
men observed in LABC and MBC, there is a strong
argument to evaluate infusional 5-FU-based regimens
in the adjuvant setting. The TOPIC trial, now closed to
recruitment, is a randomized UK multicentre study,
which compared six cycles of neoadjuvant EcisF with
standard AC (doxorubicin 60 mg/m2, cyclophospha-
mide 600 mg/m2) in patients with large operable
primary breast cancer (tumor diameter ^ 3 cm). With
over 400 patients randomized, this trial is expected to
report in the near future and will give the first direct
data comparing infusional 5-FU chemotherapy with
standard bolus treatment in the adjuvant setting. A
phase I trial, conducted by the EORTC, testing escalat-
ing doses of EcycloF in LABC has been completed
(manuscript in press) and will be followed by a phase
III trial.
The future of continuous 5-FU based chemotherapy
is likely to lie with the new oral 5-FU derivatives, since
they appear to mimic the beneficial pharmacokinetics of
infusional 5-FU without the cost and potential morbidity
of an indwelling Hickman line or Port-a-cath. Recently,
encouraging results have been reported in patients with
advanced upper gastrointestinal tract carcinoma treated
with a regimen where, in the original EcisF, the infu-
sional 5-FU was replaced by UFT, an orally available
mixture of tegafur plus uracil (a competitive inhibitor
of 5-FU catabolism) [21]. Capecitabine is another
promising 5-FU pro-drug, currently being tested in com-
bination with bolus epirubicin and cyclophosphamide in
an EORTC study for patients with locally advanced/
inflammatory breast carcinoma (CEX study).
In conclusion this study confirms the previously
reported high response rate and low toxicity profile of
EcarboF regimen. The future developments of this type
of continuous infusion 5-FU based chemotherapy are
expected to involve the use of new oral 5-FU derivatives.
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